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Background: Staphylococcus aureus skin colonization is common in patients with atopic dermatitis (AD) and is
associated with risk of skin infections. AD patients therefore often receive antibiotic treatments, including topical
treatment with fusidic acid, which have been associated with resistance development.
Objectives: To examine the prevalence of antibiotic resistance in S. aureus isolated from Danish AD patients,
with a primary focus on fusidic acid resistance and the genetic mechanisms that underlie it.
Methods: One hundred and thirty-eight S. aureus isolates collected from lesional skin (n" 54), non-lesional skin
(n"27) and anterior nares (n"57) from 71 adult AD patients were included in the study. Isolates were tested
for susceptibility to 17 selected antibiotics. S. aureus whole-genome sequences were used to examine the
genetic determinants of fusidic acid resistance (fusA or fusE mutations or carriage of fusB or fusC genes).
Results: One hundred and nine isolates (79%) were resistant to at least one of the tested antibiotics, with the
most prevalent resistances being to penicillin (55%), fusidic acid (41%) and erythromycin (11%). The primary
genetic mechanisms of fusidic acid resistance were carriage of fusC (57%) or mutations in fusA (38%). The most
prevalent S. aureus lineage was ST1 (23%). All ST1 isolates carried fusC.
Conclusions: S. aureus fusidic acid resistance, caused by either fusA mutations or fusC gene carriage, is a major
concern among AD patients. Resistant S. aureus might spread from the patients to the community, indicating
the need to reduce the use of fusidic acid in the treatment of AD.
Introduction
Atopic dermatitis (AD) is a common inflammatory skin disease
that affects 10%–20% of children and 2%–10% of adults world-
wide.1,2 The disease pathogenesis is multifactorial and includes
impaired skin barrier function and an imbalance of the
immune system with increased Th2-mediated pro-inflammatory
responses.3 AD patients are more often colonized with
Staphylococcus aureus compared with non-AD individuals [OR 19.7
for lesional skin (LS), 7.8 for non-lesional skin (NLS) and 4.5 for
anterior nares].4 This leads to increased disease severity, risk of
skin infections and prescription of antibiotics.4–6 In many countries,
including Denmark, topical treatment with fusidic acid ointment,
often in combination with corticosteroids, has been one of the pre-
ferred choices of treatment.7,8 Fusidic acid is a narrow-spectrum
antibiotic used against S. aureus. It inhibits bacterial growth by
interacting with elongation factor G (EF-G) upon ribosome binding,
thereby stalling protein synthesis9 Though fusidic acid is known to
select for resistance in S. aureus, the resistance prevalence among
clinical isolates is generally considered to be low.8 However, an
increasing prevalence of fusidic acid-resistant S. aureus, especially
isolates from skin and soft tissue infections, has been observed in
many European countries since the mid-1990s.8 Two different
mechanisms of fusidic acid resistance have been identified in clini-
cal S. aureus strains: (i) mutations in the gene encoding the drug
target EF-G (fusA) or the gene encoding ribosome protein L6 (fusE),
which interacts with EF-G upon ribosome binding; and (ii) horizon-
tal acquisition of genes (fusB or fusC), encoding proteins that block
the binding of fusidic acid to EF-G.10–15 The fusB gene is carried on
plasmids or a genomic island on the chromosome and the fusC
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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gene is found integrated in a staphylococcal cassette chromo-
some (SCC) element.13,14,16,17 Several studies have examined the
prevalence of fusidic acid resistance among S. aureus from AD
patients, reporting varying resistance frequencies (3%–33%)
depending on the country of origin.18–23 However, to our knowl-
edge, no study has yet examined the genetic mechanisms behind
fusidic acid resistance in S. aureus from AD patients.
The aim of this study was to determine the antibiotic resistance
prevalence, with a primary focus on fusidic acid resistance, among
skin and nasal S. aureus isolates from adult AD patients in
Denmark. Furthermore, we aimed to identify and characterize the
underlying genetics of fusidic acid resistance using WGS data.
Patients and methods
Patients
This study includes 71 AD patients from the outpatient clinic of the
Department of Dermatology at Bispebjerg University Hospital (Denmark),
who were all colonized with S. aureus in at least one of three sites: LS, NLS
and anterior nares. The study population is part of a larger cohort (n"101),
which has been described previously.5 Patients were included in the study
during the period 2013–15. Inclusion criteria were age18 years and pres-
ence of AD according to UK criteria.24 Exclusion criteria were pregnancy,
breastfeeding and UV therapy within the last 2 months of sampling. Upon
inclusion, AD disease severity was assessed using the Scoring Atopic
Dermatitis (SCORAD) index25 and a blood sample was collected for subse-
quent testing for filaggrin gene (FLG) mutations that are common among
Caucasians (R501X, 2282del4 and R2447X).26 Information regarding medi-
cal treatment in the 3 months prior to sampling time was obtained from all
patients. Demographic and clinical data on the patients are given in Table 1.
Bacterial isolate collection
Bacterial swabs were taken from LS, NLS and anterior nares using e-Swabs
(Copan, Brescia, Italy). Skin samples were taken by rubbing the swab
against the skin for 30 s and the nasal samples were taken by rotating the
swab three times in one of the anterior nares. S. aureus was identified by
plating samples on selective plates (chromID S. aureus plates, bioMe´rieux,
Marcy-l’E´toile, France) and a single isolate was collected from each sample
for further analysis.
Antibiotic susceptibility testing
Disc diffusion was performed using the Thermo Scientific Sensititre system
(Trek Diagnostic Systems, Thermo Fisher Scientific Inc., Waltham, MA, USA)
according to the methodology and breakpoints of EUCAST for the following
antibiotics: penicillin, fusidic acid, erythromycin, clindamycin, tetracycline,
kanamycin, rifampicin, norfloxacin, mupirocin, cefoxitin, trimethoprim/sul-
famethoxazole, ceftobiprole, ceftaroline, daptomycin, gentamicin, linezolid
and vancomycin. The panels were registered after 24 h (+1 h) of
incubation.
DNA extraction and WGS
DNA was extracted from isolates using a Qiagen DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany), with a customized pretreatment with lyso-
zyme and lysostaphin for a 30 min incubation period at 37 C. Whole-
genome sequences (2%250 paired-end sequences) were obtained using a
Nextera XT DNA Library Preparation Kit and a MiSeq sequencer (Illumina
Inc., San Diego, CA, USA). The accession numbers for the Illumina sequen-
ces for all isolates are available at the European Nucleotide Archive (ENA)
under the project identification number PRJEB18560.
Genetic typing and SNP analysis
Sequences were de novo assembled using SPAdes27 and contigs were used
for MLST the isolates in silico using MLST by T. Seeman (https://github.com/
tseemann/mlst.git). Clonal complex (CC) types were assigned from the STs
using the algorithm eBURST v3 (http://eburst.mlst.net/). spa types were
obtained by PCR and Sanger sequencing.28
SNPs in the core genome were detected using the Northern Arizona SNP
pipeline (NASP)29 by aligning de novo assembled contigs. A random
selected isolate from the study population was used as a reference.
The genetic diversity among isolates was examined by measuring the SNP
distance between isolates in Geneious v10.0.9 (Biomatters Ltd, Auckland,
New Zealand).
The genetic diversity among ST1 isolates was compared with 48 ran-
domly selected bacteraemia ST1 MSSA isolates (isolation years 2011–14)
from the Danish National Staphylococcus Surveillance Laboratory (Statens
Serum Institut, Copenhagen, Denmark). SNPs in the core genome were
identified by aligning assembled contigs from all isolates against the
genome of the ST1 isolate MSSA476 (GenBank accession number
BX571857) using NASP. A maximum-likelihood phylogeny was created in
PyML v.3.0,30 using Smart Model Selection with the Bayesian information
criterion, 100 bootstrap replicates, nearest neighbour interchange and sub-
tree priming and grafting searches for optimal tree structure. The tree was
visualized and annotated in iTOL (https://itol.embl.de/).
Identification of antibiotic resistance genes
Acquired antibiotic resistance genes, including fusB, were detected using
the application ResFinder v2.1 (settings: minimum identity 90%; minimum
coverage 90%).31 The MSSA476 genome was used as a reference for detec-
tion of the fusC gene and the SCC476 element. Identification was based on a
BLAST search as well as mapping of reads against the reference. For
12 samples, which had,10-fold coverage of the fusC gene, a fusC-specific
PCR was performed using the primers and procedure described previously32
Table 1. Demographic and clinical characteristics of the AD study popu-
lation (n"71)
Variable
Number of patients (%),
unless otherwise stated
Gender male 33 (46.5)
female 38 (53.5)
Age (years) mean (range) 36.7 (18–77)
SCORAD mean (+SD) 35.0 (+15.3)
FLG status WT 38 (53.5)
mutations 26 (36.6)
unknown 7 (9.9)
Systemic antibiotic
treatmenta
yes 15 (21.1)
no 56 (78.9)
Topical fusidic acid
treatmenta
yes 7 (9.9)
no 64 (90.1)
Topical corticosteroid
treatmenta
yes 50 (70.4)
no 18 (25.4)
unknown 3 (4.2)
Systemic treatment
for ADa,b
yes 22 (31.0)
no 49 (69.0)
aWithin 3 months prior to sample collection.
bAzathioprine, alitretinoin, mycophenolate mofetil, methotrexate or
prednisolone.
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in order to confirm the WGS results. Resistance-associated mutations in
fusAand fusEwere identified by aligning the gene sequences from each iso-
late to the WT gene sequences using MSSA476 as a reference (fusA,
SAS0505; fusE, SAS2126). All genetic analyses were performed using CLC
bio’s Genomics Workbench v8.5.1 (Qiagen, Aarhus, Denmark) if nothing
else is stated.
In silico identification of a novel fusB plasmid
In order to identify the location of the fusB gene in three highly similar iso-
lates (7–75 SNPs separating them) originating from a single patient, a
BLAST search using the largest de novo assembled contig containing the
resistance gene was performed against NCBI’s nucleotide sequence data-
base, with the best hit being S. aureus plasmid pSA564 (NCBI accession
number CP010891). The contig coverage was.4-fold higher than the aver-
age coverage of the chromosome, indicating a plasmid origin. The contig
was circularized after removal of a 127 bp repetitive region and the splicing
was verified by reference assembly using the original whole-genome
sequence data. An alignment of the novel plasmid and the closest NCBI hit,
pSA564, was performed using MAUVE as implemented in Geneious v10.0.9
to identify plasmid differences. The assembled fusBplasmid was annotated
using Prokka v1.1133 and submitted to NCBI’s nucleotide sequence data-
base under the accession number MF622050.
Ethics
The study was approved by the local Ethics Committee (project number
1-2014-039) and the Danish Data Protection Agency (project number
01767 BBH- 2012-019). Patients gave informed consent to participate in
the study.
Statistics
The non-parametric Mann–Whitney U-test was used to test for differences
in the pairwise SNP distance between groups. Statistical analysis was per-
formed in R v3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Isolate collection
One hundred and thirty-eight S. aureus isolates collected from LS
(n"54), NLS (n"27) or anterior nares (n"57) from 71 adult AD
patients were included in the study. The isolate collection was clo-
nally diverse and consisted of 21 different STs, which could be
grouped into 17 different CCs and a singleton (Table S1, available
as Supplementary data at JAC Online). The most prevalent CC
types were CC1 (n"32; ST1), CC15 (n"27; ST15 and ST582) and
CC45 (n"19; ST45 and ST508). Fifty-one different spa types were
identified (Table S2). For 42 of 46 patients (91%) with more than
one S. aureus-positive swab, the same clonal S. aureus type was
isolated from the different sample sites. Pairwise SNP distance
analysis showed that S. aureus isolates from the same patient
(mean SNP distance: 1677) were significantly more similar com-
pared with isolates collected from different patients (mean SNP
distance: 27045) (P,0.001) (Table S3).
In order to examine whether the high frequency of ST1 isolates
was due to local transmission between AD patients at the outpa-
tient clinic at the hospital, the genetic similarity between ST1 iso-
lates (n"32) from the AD patients and ST1 MSSA isolates (n"48)
from Danish bacteraemia patients was investigated in a phyloge-
netic analysis. The isolates from AD patients were dispersed
throughout the phylogeny between different bacteraemia isolates
(Figure S1). Also, a pairwise SNP distance analysis showed that
S. aureus isolates from distinct AD patients (mean SNP distance:
291) were not genetically more similar compared with S. aureus
from bacteraemia patients (mean SNP distance: 299) (P"0.4)
(Table S4).
Antibiotic resistance prevalences
One hundred and nine of the 138 S. aureus isolates (79%) were
resistant to at least one of the tested antibiotics. The most preva-
lent types of resistance were resistance to penicillin (55%), fusidic
acid (41%) and erythromycin (11%) (Table 2). Only a few S. aureus
isolates were resistant to any other antibiotic tested and all were
susceptible to methicillin. Resistance genes identified in the resist-
ant S. aureus isolates are given in Table S5.
At the patient level, 55 out of the 71 AD patients (78%) carried
an antibiotic-resistant strain in at least one of the sampled sites
and 27 patients (38%) were colonized with a fusidic acid-resistant
strain. The overall antibiotic susceptibility profile across sampling
sites (LS, NLS and anterior nares) was identical in 35 out of
46 patients (76%) with more than one positive S. aureus swab. For
the remaining 24%, there was no correlation of pattern to the site
of sampling.
Genetic determinants of fusidic acid resistance
Carriage of one or more of the known genetic determinants of
S. aureus fusidic acid resistance was identified in all the fusidic
acid-resistant isolates (Table 3). The predominant types of resist-
ance were carriage of fusC (57%) and point mutations in fusA
(38%). Among nasal isolates, the prevalence of fusC gene carriage
(65%) was remarkably higher than the prevalence of fusA muta-
tions (30%), but no corresponding differences were observed
among skin-colonizing isolates (LS and NLS). The fusA mutations
were identified in five different STs, whereas the fusC gene was
only identified in ST1 isolates (Figure S2).
Eight different fusA mutations causing amino acid substitutions
in EF-G were detected in the resistant isolates (Table S6). A single
isolate contained four different mutations, of which two (V90I and
L461S) have been reported previously to be associated with fusidic
acid resistance in S. aureus.34 It is unknown whether the last two
Table 2. Antibiotic resistance prevalence
Antibiotic
Prevalence [count (%)]
total
(n"138)
LS
(n"54)
NLS
(n"27)
anterior nares
(n"57)
Penicillin 76 (55) 29 (54) 15 (56) 32 (56)
Fusidic acid 56 (41) 21 (39) 15 (56) 20 (35)
Erythromycin 15 (11) 4 (7) 5 (19) 6 (11)
Norfloxacin 3 (2.2) 1 (2) 1 (4) 1 (2)
Daptomycin 2 (1.5) 1 (2) 1 (4) 0
Kanamycin 1 (0.7) 1 (2) 0 0
Gentamycin 1 (0.7) 1 (2) 0 0
Tetracycline 1 (0.7) 1 (2) 0 0
Mupirucin 1 (0.7) 0 0 1 (2)
Edslev et al.
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mutations (P286T and P406T) are associated with resistance to
fusidic acid.
Three isolates, all from the same patient, had both a missense
mutation in fusA (V86A) and a nonsense mutation in fusE
(Y168stop) (Table S6). As neither of the two mutations has been
described previously, it is uncertain whether both mutations, or only
one of them, are causing the observed resistance to fusidic acid.
The fusB gene was identified in three isolates, all originating
from a single patient. The gene was localized on a novel 28623 bp
plasmid, which was very similar to S. aureus plasmid pSA564 (NCBI
accession number CP010891), but contained an additional region
(3173 bp) in which the fusB gene was integrated. The plasmid was
named pSA564-fus and submitted to NCBI’s nucleotide sequence
database (accession number MF622050).
The fusC gene was integrated in an SCC476 element and was
identified in all ST1 isolates in this study (n"32).
Topical fusidic acid treatment in relation to resistance
Seven of the 71 AD patients had been treated topically with fusidic
acid within 3 months prior to the sample collection (Table 1) and
5 of these had been treated within the last week. Fusidic acid-
resistant S. aureus was isolated from six of these patients (86%),
whereas 21 out of 64 (33%) of the non-treated patients were
colonized with fusidic acid-resistant S. aureus. At the bacterial
level, 17 out of 18 isolates (94%) collected from patients who had
received topical treatment were tested to be resistant to fusidic
acid. In comparison, 39 out of 120 (33%) of the isolates collected
from non-treated patients were resistant.
Eleven of the 18 isolates from patients recently treated with
fusidic acid carried the fusC gene, 3 had fusA mutations and 3 had
a combination of fusA and fusEmutations.
Discussion
To our knowledge, the present study is the first to identify the
genetic mechanisms underlying fusidic acid resistance in S. aureus
isolated from AD patients. The predominant genetic determinants
were carriage of fusC in an SCC476 element and fusA point muta-
tions. There were no major differences in the prevalence of fusC
carriage and fusA mutations among skin-colonizing isolates, but
the prevalence of fusC (65%) was notably higher than the preva-
lence of fusA mutations (30%) in nasal isolates. Mutation in fusA is
known to have a high fitness cost for S. aureus.10 This might explain
why fewer nasal isolates carried the mutations, as topical fusidic
acid preparations are only applied to the skin and S. aureus coloniz-
ing the nares have thus no advantage in harbouring fusA muta-
tions, contrary to skin-colonizing bacteria. In comparison, carriage
of the fusC gene has been shown not to impose a significant fitness
cost in S. aureus.15 Due to the high fitness cost related to fusA
mutations, it might be that only a minor subset of S. aureus isolates
in a host contain such mutations. It is thus a limitation of the
present study that only one isolate was selected from each of the
sampling sites, as the prevalence of S. aureus with fusA mutation
might have been underestimated.
Forty-one percent of S. aureus isolates from the Danish AD
patients were resistant to fusidic acid. In comparison, 16% of all
S. aureus from bacteraemia cases in Denmark in 2015 were resistant
to this antibiotic35 and in a study of asymptomatic nasal carriers
(n"6814) in 2010–11 from nine European countries only 2.8% of
MSSA isolates were fusidic acid resistant.36 It is not surprising that
the resistance prevalence was higher among S. aureus from AD
patients as these patients are frequently treated with fusidic acid,
which probably leads to selection of resistant strains. In accordance,
we found that the prevalence of resistant isolates was higher among
patients who had been treated topically with fusidic acid within the
last 3 months compared with those who had not been treated.
However, the group of patients who had received topical fusidic acid
treatment was too small (n"7) for any conclusions to be drawn.
Another study in the UK recently examined the effect of antibi-
otic treatments on S. aureus resistance development in children
with AD.18 They found that topical fusidic acid treatment was asso-
ciated with a significant increase in the resistance prevalence
2 weeks after the treatment, but not after 3 months, indicating
that topical treatment only causes short-term resistance selection.
However, they still found that the frequency of skin-colonizing
S. aureus that were fusidic acid resistant was relatively high after
the 3 month period (25%). Likewise, we found that 33% of
S. aureus isolates from patients who had not been treated topically
with fusidic acid in the past 3 months were resistant. This indicates
that reducing the prevalence of resistant S. aureus in AD patients
requires more restrictive regulation of the usage of topical fusidic
acid. Such regulations were issued in Sweden in the early 2000s.
The national recommendation to reduce the consumption of fusi-
dic acid ointments in Sweden was followed by a nationwide
decrease in the prevalence of resistant S. aureus isolated from
patients with skin infections.37
In addition to fusidic acid, the present study also evaluated
S. aureus susceptibility to 16 other selected antibiotics. Of these,
resistance prevalences.10% were only observed for penicillin and
erythromycin. However, the percentage of isolates being penicillin
resistant (55%) was lower than the resistance prevalence
observed among S. aureus from Danish bacteraemia patients
(71%).35 Also, there was no significant difference in the prevalence
of erythromycin resistance between AD isolates (11%) and bacter-
aemia isolates (7%). Thus, resistance to antibiotics other than fusi-
dic acid is not an issue restricted to AD.
The frequency of ST1 S. aureus in this study (23%) was notably
higher than the frequency among Danish asymptomatic nasal
Table 3. Genetic resistance determinants among fusidic acid-resistant
isolates
Prevalence [count (%)]a
total (n"56) LS (n"21) NLS (n"15)
anterior nares
(n"20)
fusA mutations 21 (38) 9 (43) 6 (40) 6 (30)
fusE mutations 3 (5) 1 (5) 1 (7) 1 (5)
fusB geneb 3 (5) 1 (5) 1 (7) 1 (5)
fusC geneb 32 (57) 11 (52) 8 (53) 13 (65)
aThree isolates had mutation in both fusA and fusE; thus, the sum of the
prevalence count of the four genetic determinants exceeds the total
count of resistant isolates.
bAll isolates had genes with 100% identity and 100% coverage to refer-
ence genes, with the exception of fusC in one isolate (100% identity,
.95% coverage).
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S. aureus carriers (7.7%)38 and Danish S. aureus bacteraemia
patients (8.6%).39 A likely explanation of the higher prevalence of
ST1 S. aureus colonizing AD patients could be the presence of fusC,
which was identified in all the studied ST1 isolates. Frequent treat-
ments with fusidic acid among AD patients could lead to clonal
selection and expansion of fusC-positive ST1 S. aureus in this patient
group. Carriage of fusidic acid resistance genes has previously
been shown to have a significant influence on the dissemination of
S. aureus clones.16,17,40 WGS data from the Danish National
Staphylococcus Surveillance Laboratory have shown that 50% of
sequenced ST1 MRSA (n"79) isolated from either infections or
asymptomatic carriers in 2007–14 also carried the fusC gene (data
not shown). If these ST1 MRSA strains were to be introduced into the
AD patient population, fusidic acid treatment could lead to MRSA
selection and spread, as has been the case in New Zealand.16
Factors other than fusC carriage, such as clone-specific viru-
lence genes or host genetics, could also have an influence on the
selection of ST1 S. aureus in AD. In accordance, we have recently
shown a possible association between ST1 S. aureus colonization
and mutations in FLG, encoding the human skin barrier protein
filaggrin, in AD patients.5 The high frequency of ST1 S. aureus colo-
nization in the AD patient group could possibly also be caused by
local transmission between patients at the outpatient clinic.
However, ST1 isolates from different AD patients were not geneti-
cally more similar than ST1 isolates from Danish bacteraemia
patients, thus excluding a local transmission at the clinic.
In summary, we found here that a high proportion of S. aureus
colonizing skin and nares in Danish AD patients are resistant to
fusidic acid and that the predominating genetic basis of resistance
was carriage of fusCor mutations in fusA. The fusCgene was identi-
fied in all ST1 S. aureus isolates and is likely a major driver for the
success of the ST1 S. aureus clone in the AD population. The skin
and nares of AD patients can thus act as a reservoir for fusidic acid-
resistant S. aureus that can spread to the community. This sup-
ports the argument that usage of fusidic acid preparations in the
treatment of AD should be restricted.
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